Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus

Bornstein, Jacob; Heifetz, Sigal; Kellner, Yehudith; Stolar, Zmira; Abramovici, H

doi:10.1016/s0002-9378(98)70631-3

Cited by 79 publications

(38 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date there are no other studies regarding the patient-defined therapeutic benefit of treatment interventions in LS. Marked benefit in terms of symptoms control has been shown for clobetasol and calcineurin inhibitors [4,13,14,42,43,44,45]. There is one randomized trial comparing the calcineurin inhibitor pimecrolimus with clobetasol, demonstrating superiority of clobetasol [46].…”

Section: Discussionmentioning

confidence: 99%

Health-Related Quality of Life and Patient-Defined Benefit of Clobetasol 0.05% in Women with Chronic Lichen Sclerosus of the Vulva

Schwegler¹,

Schwarz²,

Eulenburg

et al. 2011

Dermatology

View full text Add to dashboard Cite

Background: This study investigates the health-related quality of life in patients with vulvar lichen sclerosus (LS) and the patient-defined therapeutic benefit of clobetasol. Methods: A survey analysis of 96 women with LS after treatment with clobetasol was performed. Quality of life was assessed with the Skindex-29. The Patient Benefit Index (PBI) was used to determine the therapeutic benefit. Results: The overall response rate was 59.2%. Quality of life was most impaired by somatic symptoms (scale ‘Symptoms’ score 3.2) and emotional stress (scale ‘Emotions’ score 3.1), while social interactions (scale ‘Functioning’ score 1.9) played an inferior role (p < 0.001). Primary therapeutic goals ‘to have confidence in the therapy’ and ‘to be free of itching’ were achieved in 73.2 and 69.0% of patients who indicated the goal applied to them. The global PBI score was 3.06. In 93.2% of patients it was >1, indicating a potential benefit from clobetasol. Conclusion: Topical clobetasol is of potential therapeutic benefit for patients with vulvar LS and might therefore improve quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Health-Related Quality of Life and Patient-Defined Benefit of Clobetasol 0.05% in Women with Chronic Lichen Sclerosus of the Vulva

Schwegler¹,

Schwarz²,

Eulenburg

et al. 2011

Dermatology

View full text Add to dashboard Cite

show abstract

“…The indicated remission rates in selected reports vary from 20% to 97.6% [5,6,[8][9][10][11][12][13][14][15][16][17][18]. However, Bornstein and colleagues [8] reported that applications of testosterone have no role in the treatment of LS and Sideri and colleagues [15] suggested that testosterone was no better than petrolatum alone (66.5% vs. 75%). Since the number of patients involved in the majority of these studies is low, the controversy about the use of topical testosterone for vulvar LS is still alive.…”

Section: Discussionmentioning

confidence: 99%

“…Limited data comparing response rates to testosterone and corticosteroid treatments are available from small-scale retrospective and randomized clinical trials [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Topical testosterone versus clobetasol for vulvar lichen sclerosus

Ayhan

Güven

et al. 2007

International Journal of Gynecology & Obstetrics

View full text Add to dashboard Cite

show abstract

“…The goal of this therapy was to thicken the vulvar skin and improve symptoms. Observational studies suggested that up to 80% of patients had symptomatic relief with testosterone [16]. However, treatment with topical testosterone may have had untoward side effects resulting from significant systemic absorption of testosterone, and up to 40% of patients showed at least one clinical of symptom of hyperandrogenism within a month of starting therapy [17].…”

Section: Treatment Of Lichen Sclerosusmentioning

confidence: 99%

Lichen sclerosus and other conditions mimicking vulvovaginal candidiasis

Nyirjesy

2002

Curr Infect Dis Rep

View full text Add to dashboard Cite

For many women with chronic vulvovaginal symptoms, overdiagnosis of vulvovaginal candiasis (VVC) is an unfortunate tendency. In women with chronic vulvar itching or burning, a vulvar non-neoplastic epithelial disorder is a relatively frequent diagnosis. Although controversy persists about the nomenclature for these disorders, there seems to be a relatively clear consensus with lichen sclerosus. This chronic inflammatory skin disease affects primarily the female vulvar and perianal areas. Left untreated, it may lead to chronic scarring of the vulva with an associated loss of architecture. The etiology remains unknown, although infectious, genetic, and autoimmune causes have been suggested. Most patients will respond to potent topical corticosteroids. Treatment of associated conditions such as atrophic vaginitis or complicated VVC is sometimes necessary. Surgery should be considered in patients with severe scarring.

show abstract

Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus

Cited by 79 publications

References 14 publications

Health-Related Quality of Life and Patient-Defined Benefit of Clobetasol 0.05% in Women with Chronic Lichen Sclerosus of the Vulva

Health-Related Quality of Life and Patient-Defined Benefit of Clobetasol 0.05% in Women with Chronic Lichen Sclerosus of the Vulva

Topical testosterone versus clobetasol for vulvar lichen sclerosus

Lichen sclerosus and other conditions mimicking vulvovaginal candidiasis

Contact Info

Product

Resources

About